American Journal of Managed Care

The American Journal of Managed Care is a monthly medical journal that undergoes peer review and is released by Managed Care & Healthcare Communications, LLC. In 2009, it achieved an impact factor of 2.74.

International, National, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#155122

United States

#50609

Health/Health Conditions and Concerns

#106

Traffic sources

Monthly visitors

Articles

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

4 days ago | ajmc.com | Giuliana Grossi |Skylar Jeremias |Eva Szigethy |Benjamin Cohen

The Specialty Medical Home model is reshaping care for people living with inflammatory bowel disease (IBD). IBD, which includes Crohn disease and ulcerative colitis, is a complex, chronic condition that affects millions of people and requires more than just medical management.
Lorundrostat Yields Promising Results for Treatment of Hypertension in Patients with CKD and Albuminuria

1 week ago | ajmc.com | Giuliana Grossi

Lorundrostat (Mineralys Therapeutics) significantly lowered both systolic blood pressure and proteinuria in patients with hypertension and chronic kidney disease (CKD), according to positive topline results from Mineralys Therapeutics’ phase 2 Explore-CKD trial (NCT06150924), supporting its potential as a dual-action treatment for cardiovascular and renal protection.1 “Prolonged elevations in blood pressure in patients with compromised renal function can damage the small blood vessels in the...
Clinical Trials Financially Beneficial for Patients: Eric Lander, MD

1 week ago | ajmc.com | Julia Bonavitacola |Eric M. Lander

Eric Lander, MD, site research leader at Minnesota Oncology, spoke with The American Journal of Managed Care®after participating in the Institute for Value-Based Medicine® meeting held in Minneapolis on June 17. The panel Lander participated on focused on several topics revolving around National Comprehensive Cancer Network guidelines and how their recommendations are practiced in real-world settings.
FDA Approves Tafasitamab for Follicular Lymphoma

1 week ago | ajmc.com | Skylar Jeremias

Good news for adults battling a specific type of blood cancer: on June 18, 2025, the FDA gave its stamp of approval to tafasitamab-cxix, known commercially as Monjuvi, to be used in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).1 This approval offers a promising new treatment option for patients whose disease has returned or hasn't responded to previous therapies.
Cost Will Be Massive Barrier in Access to Lenacapavir After Approval in the US: Gordon Crofoot, MD, PA

1 week ago | ajmc.com | Julia Bonavitacola |Gordon Crofoot

Cost could make lenacapavir (Sunlenca; Gilead) inaccessible for people who would like to use it as a means of pre-exposure prophylaxis (PrEP) in the prevention of HIV, explained Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center. Although the treatment is nearly 100% effective, the price point could make rollout slow in vulnerable populations. This transcript has been lightly edited for clarity; captions are auto-generated.
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

1 week ago | ajmc.com | Julia Bonavitacola |Colleen Kelley

The prevention of HIV could monumentally shift followong the FDA approval of lenacapavir on June 19, as the twice-yearly long-acting injectable form of pre-exposure prophylaxis (PrEP) demonsstrated high efficacy in preventing HIV in early trials.
AJMC® in the Press, June 20, 2025

1 week ago | ajmc.com | Julia Bonavitacola

Author(s):Fact checked by: The current prior authorization process negatively impacts patient care, leading some practices to switch to a cash-only model. A report reveals that 45% of insured adults received unexpected medical bills for services they believed were covered. 17% of insured adults were denied coverage for services recommended by their physicians, highlighting systemic issues in health insurance.
Venetoclax Effective in Older Patients With CLL

1 week ago | ajmc.com | Jared Kaltwasser

Venetoclax (Venclexta; Abbvie, Genentech) has a high response rate in octogenarians with chronic lymphocytic leukemia (CLL), but clinicians should expect treatment-management challenges such as temporary stops.1Those are among the key findings of a new retrospective study that examined the safety and efficacy of the BCL-2 inhibitor in older patients. The report was published inBlood Advances.
Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

1 week ago | ajmc.com | Laura Joszt

Operationalizing chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for treating multiple myeloma and lymphoma requires managing an intricate balance of cost-effectiveness, patient care delivery, and emerging treatment strategies, according to panelists at an Institute for Value-Based Medicine (IVBM) event presented by The American Journal of Managed Care in Cleveland, Ohio.
Value-Based Care Calls for Putting Novel Therapies Closer to Patients

1 week ago | ajmc.com | Mary Caffrey

The last time The American Journal of Managed Care (AJMC) hosted a meeting in Princeton, New Jersey, was 2014, as millions of Americans were gaining health coverage under the Affordable Care Act—some for the first time in their lives.